Most patients presenting with allergies are first seen by primary care
health professionals. The perceived knowledge gaps and educational needs
were recently assessed in response to which the LOGOGRAM Task Force was
established with the remit of constructing pragmatic flow-diagrams for
common allergic conditions in line with an earlier EAACI proposal to
develop simplified pathways for the diagnosis and management of allergic
diseases in primary care. To address the lack of accessible and
pragmatic guidance, we designed flow-diagrams for five major clinical
allergy conditions: asthma, anaphylaxis, food allergy, drug allergy and
urticaria. Existing established allergy guidelines were collected and
iteratively distilled to produce five pragmatic and accessible tools to
aid diagnosis and management of these common allergic problems.
Ultimately, they should now be validated prospectively in primary care
settings.
Most patients presenting with allergies are first seen by primary care health professionals. The perceived knowledge gaps and educational needs were recently assessed in response to which the LOGOGRAM Task Force was established with the remit of constructing pragmatic flow diagrams for common allergic conditions in line with an earlier EAACI proposal to develop simplified pathways for the diagnosis and management of allergic diseases in primary care. To address the lack of accessible and pragmatic guidance, we designed flow diagrams for five major clinical allergy conditions: asthma, anaphylaxis, food allergy, drug allergy, and urticaria. Existing established allergy guidelines were collected and iteratively distilled to produce five pragmatic and
BACKGROUND Data on epidemiology of drug hypersensitivities (DH) is retrieved from specific registrars, electronic health records of health care systems, pharmacovigilance databases, and specific allergy work-upcentered databases. The Drug Allergy and Hypersensitivity Database (DAHD) of the Allergy Unit in Montpellier, France has been questioned several times throughout the years, to provide answers to specific questions in drug allergy epidemiology.
Purpose of review
The aim of this study was to review the practice of general practitioners (GPs) in regard to the diagnosis and management of drug hypersensitivity reactions (DHRs) to identify major challenges and to facilitate the development of decision support tools to GPs confronted with DHRs patients.
Recent findings
DHRs are still a challenge in the GPs clinical practice, which implies difficulties in clinical decisions and referral to allergy specialists.
Summary
DHRs can range from mild to severe and even life-threatening. Drugs are the main cause of anaphylaxis deaths in most countries. Most DHRs are firstly seen by GPs, paediatricians or emergency doctors. However, our systematic review demonstrated difficulties in differentiating DHRs from other drug side effects. Most DHRs epidemiological data are from hospital and emergency departments, which may not reflect the real-life experience in primary care. GPs should be aware of the alert signs of DHRs: the involvement of other systems beyond the skin and/or atypical skin/ mucosal involvement, which mandated immediate referral to an emergency department. Data still stress difficulties in the recognition of DHRs clinical manifestations and highlight the need for decision aids to support their management by GPs. Structured clinical history and clinical examination are key diagnostic tools. Reasons for referring to allergy specialists based on the literature are to investigate cause, to undergo specific procedure, such as desensitization and to identify well tolerated, alternative drugs.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.